China Baoyuan Investment Co., Ltd. is a wholly-owned subsidiary of China National Nuclear Corporation. China Baoyuan Investment Co., Ltd. focuses on the whole industrial chain of nuclear technology application, starting from the nuclear, not just the nuclear. Through the strategic path of controlling the source, strengthening the core and expanding the application, we will build three industrial systems: nuclear technology products and services, nuclear characteristic medical care and modern services.
As a specialized company in the development of nuclear technology application industry of China National Nuclear Corporation, China Baoyuan is committed to making nuclear technology create happiness for mankind, and is responsible for implementing the medium-and long-term strategic objectives of the development of nuclear technology application industry of China National Nuclear Corporation, so as to become an internationally renowned nuclear technology application industry group. China Baoyuan has more than 200 member companies, which are located in Beijing, Shenzhen, Suzhou, Chengdu, Qingdao, Xi, Nanjing and other large and medium-sized cities 10, with its headquarters in Beijing.
Brief Introduction of China Baoyuan Investment Company:
China Baoyuan Investment Co., Ltd. (hereinafter referred to as China Baoyuan) is a wholly-owned specialized company of China National Nuclear Corporation (hereinafter referred to as CNNC) to develop the nuclear technology application industry, and is responsible for implementing the medium and long-term development strategy of CNNC's nuclear technology application industry. The predecessor of the enterprise can be traced back to the Second Machinery Department and the Sixth Bureau. At present, China Baoyuan's business covers most fields of nuclear technology application, forming an industrial chain of nuclear technology application from technology, products to service applications.
China Baoyuan serves more than 1 10,000 medical institutions nationwide, with a domestic market share of over 70%; 14C respiratory diagnostic products account for more than 90% of the domestic market share, and 13C respiratory diagnostic products account for more than 50% of the domestic market share; Master the independent production technology of medical 60Co source, with a market share of 90%; The annual output of industrial 60Co is about 7 million curies, ranking third in the world.
Reference to the above content: Baidu Encyclopedia-China Baoyuan Investment Co., Ltd.